 |
|
©2000 Intelligent Systems |
Sharon
Correia Aderis
Pharmaceuticals Named Among Top 15 Biotech
Companies of 2003 By FierceBiotech Aderis
Pharmaceuticals was selected from more than
1,000 privately held biotech companies for their
vision, management expertise and overall
potential to change how doctors treat disease. Hopkinton,
MA - Feb
3, 2003 - Aderis
Pharmaceuticals, a biopharmaceutical company
with four product candidates in clinical
development for the treatment of central nervous
system, cardiovascular and renal disorders,
today announced that it has been selected as one
of “The Fiercest 15” biotechnology companies
of 2003 by FierceBiotech, an internationally
recognized email newsletter for the biotech
industry. Aderis Pharmaceuticals was selected
from more than 1,000 privately held biotech and
medical device companies for their vision,
management expertise, and overall potential to
change how doctors treat disease. “Effective
treatments for central nervous system disorders
remain few and far between,” said Kevin
DeGeeter, editor of FierceBiotech. “We think
Aderis has a portfolio of winning drug
candidates.” Aderis
Pharmaceuticals’ lead product candidate,
rotigotine CDS, is currently in Phase III
clinical trials for the treatment of
Parkinson’s disease. It recently successfully
completed a Phase II trial for the treatment of
Restless Legs Syndrome. Rotigotine CDS, a novel
dopamine agonist formulated as a once-a-day
transdermal patch, delivers a steady level of
medication over a 24-hour period, an approach
that could potentially prevent side effects and
symptoms caused by currently available oral
therapies. The Company, with its partners, is
also conducting late-stage clinical trials with
product candidates for the treatment of atrial
fibrillation and the diagnosis of cardiovascular
disease. The Company has also begun development
of a product candidate to treat diabetic foot
ulcers. "Aderis
Pharmaceuticals’ possesses many qualities that
we believe differentiate us from other companies
in our field, including proven skill in
designing and conducting early-stage clinical
trials to identify promising candidates; the
necessary alliances with larger pharmaceutical
partners to carry these products to market; and
the guidance of a management and advisory team
with extensive industry experience," said
Peter Savas, Chairman, President and Chief
Executive Officer of Aderis Pharmaceuticals.
"We are very pleased to be recognized by
FierceBiotech for our excellence in drug
development." The Fiercest 15
celebrates the spirit of being “fierce” –
daring to be innovative and forward-looking,
even in a difficult market environment. The list
is available in today’s issue of FierceBiotech
and on the FierceBiotech Web site at
www.fiercebiotech.com. FierceBiotech is
a daily email briefing read by more than 20,000
executives in more than 75 countries. Since its
inception in October 2001, FierceBiotech has
been recognized as a must-read source of news
and intelligence for the biotech industry. About Aderis
Pharmaceuticals Aderis
Pharmaceuticals is a biopharmaceutical company
engaged in small molecule drug development to
treat central nervous system, cardiovascular and
renal disorders. The Company currently has four
product candidates in six clinical development
programs. Aderis Pharmaceuticals has a strategic
alliance with Schwarz Pharma AG, which develops
rotigotine CDS, a dopamine agonist for the
treatment of Parkinson’s disease using a
proprietary, once-a-day, continuous delivery
transdermal patch, currently in Phase III
trials. The Company also has alliances with
Fujisawa Healthcare, Inc. and King
Pharmaceuticals. Aderis Pharmaceuticals’
product pipeline includes receptor agonists and
antagonists for the diagnosis and treatment of
Parkinson’s disease, Restless Legs Syndrome,
atrial fibrillation, coronary artery disease and
wound healing in diabetic foot ulcers. Founded
in 1994, Aderis Pharmaceuticals is headquartered
in Hopkinton, Massachusetts and has research
facilities in Richmond, Virginia. Certain
statements in this news release that are not
historical fact constitute “forward-looking
statements.” Such forward-looking statements
involve known and unknown risks, uncertainties
and other factors which may cause the actual
results of Aderis Pharmaceuticals to be
materially different from historical results or
from any results expressed or implied by such
forward-looking statements. Such statements
include, but are not limited to, any statements
relating to the Company’s development programs
and any other statements that are not historical
facts. Such statements involve risks and
uncertainties, including but not limited to,
those risks and uncertainties relating to
difficulties or delays in development, testing,
regulatory approval, production and marketing of
the Company’s drug candidates, unexpected
adverse side effects or inadequate therapeutic
efficacy of the Company’s drug candidates that
could slow or prevent product development or
commercialization, the uncertainty of patent
protection for the Company’s intellectual
property or trade secrets and the Company’s
ability to obtain additional financing if
necessary. Such statements are based on
management’s current expectations, but actual
results may differ materially due to various
factors, some but not all of which may have been
mentioned above.
# # # # |
|
